Clinical Trials Browser

Phase 3 × Brentuximab Vedotin × 90 days × Clear all

NCT05675410 2026-03-19

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

Phase 3 Recruiting

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT02166463 2026-03-18

Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma

Phase 3 Active not recruiting

600 enrolled 14 charts 1 FDA

Ann Arbor Stage IIB Hodgkin Lymphoma

NCT04404283 2026-03-17

ECHELON-3

Phase 3 Active not recruiting

238 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT01712490 2026-02-27

A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma

Phase 3 Completed

1,334 enrolled 23 charts

Hodgkin Disease, Lymphoma

NCT02684292 2026-02-18

MK-3475-204

Phase 3 Completed

304 enrolled 2 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease

NCT04685616 2026-02-18

RADAR

Phase 3 Recruiting

Hodgkin Disease